NIOX Group explained

NIOX Group plc
Type:Public limited company
Foundation:2006[1]
Founders:Steve Harris and Charles Swingland[2]
Location:Oxford, United Kingdom
Key People:Ian Johnson
(Executive Chairman)
Michael Roller
(CFO)
Jonathan Emms
(COO)
Industry:Medical Devices
Revenue:£36.8 million (2023)[3]
Homepage:www.niox.com

NIOX Group PLC is a company focussed on treating people suffering from respiratory diseases through its NIOX (Nitric Oxide) range of FeNO (Fractional Exhaled Nitric Oxide) devices which help diagnose and manage asthma.[4] The company is a provider of point-of-care FeNO (Fractional Exhaled Nitric Oxide) measurement and monitoring. It is listed on the London Stock Exchange.

History

The company was founded by Steve Harris and Charles Swingland as Circassia Group in 2006.[5] It was the subject of an initial public offering in March 2014.[6]

In December 2019, Steve Harris announced that he was resigning as CEO of the company. Ian Johnson took over as Executive Chairman of the company, Michael Roller replaced Julien Cotta as the Chief Financial Officer, and Jonathan Emms, who was appointed to the company in September 2019, became the Chief Operating Officer.[7]

The company also announced its withdrawal from the COPD (chronic obstructive pulmonary disease) business in April 2020, with a proposed transfer of assets to, and termination of agreement with, AstraZeneca for consideration to be set off against debt and accrued interest.[8]

In 2022 the company changed its name from Circassia Group plc to NIOX Group plc.[9]

Operations

NIOX Group has direct offices in the United Kingdom, United States, Germany, Sweden and China. The company also operates through a distribution model, working with partner companies in order make NIOX available throughout the globe.[10]

NIOX

NIOX (Nitric Oxide) is a FeNO testing device. Using visual aids and sounds, NIOX provides an easy to use test experience to help patients perform FeNO (Fractional Exhaled Nitric Oxide) tests.[11]

FeNO aids healthcare professionals with the diagnosis and management of asthma.

External links

Notes and References

  1. Web site: Fundamentals for Circassia Pharmaceuticals Ord 0.08p. The Telegraph. 23 August 2014.
  2. Web site: Fundamentals for Circassia Pharmaceuticals Ord 0.08p. The Telegraph. 23 August 2014.
  3. Web site: Final Results 2023. NIOX Group plc. 4 December 2024.
  4. Web site: Company. live. 29 March 2021. Circassia. en-US. https://web.archive.org/web/20040324190950/http://circassia.com:80/ . 2004-03-24 .
  5. Web site: Fundamentals for Circassia Pharmaceuticals Ord 0.08p. The Telegraph. 23 August 2014.
  6. Web site: Circassia IPO Fuels Optimism on European Biotech. Wall street Journal. 13 March 2014. 23 August 2014.
  7. Web site: Circassia appoints Jonathan Emms to new COO role. 12 August 2019. Sharecast. 29 March 2021.
  8. Web site: Circassia pulls plug on AZ agreement. 9 April 2020. PharmaTimes. 29 March 2021.
  9. Web site: Circassia Group plc renames to NIOX Group plc . 1 September 2022. London Stock Exchange. 23 November 2023.
  10. Web site: Locations. 2023-11-23. NIOX. en-US.
  11. Web site: FeNO by NIOX Enhanced Asthma Management United States. 2021-03-29. NIOX.com. EN.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "NIOX Group".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.